Recent trials into retatrutide, a dual GIP and GLP-1 compound, are showing promising benefits for obesity therapy. Preliminary human trials have indicated substantial losses in overall weight and improvements in associated health markers , notably for individuals with obesity . Ongoing research concentrate on evaluating the sustained safety char… Read More